NASDAQ$MDXG
Mimedx Group Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Mimedx's financial performance reflected a 7% year-over-year net sales growth and a GAAP net income of $18 million.
MiMedx reported a 7% increase in net sales, reaching $87 million for the second quarter of 2024. The company's GAAP net income was $18 million, with an Adjusted EBITDA of $20 million, representing 23% of net sales. The growth was driven by AMNIOEFFECT® and EPIEFFECT® products, despite competitive challenges.
- Net sales for Q2 2024 reached $87 million, a 7% increase year-over-year.
- GAAP net income for Q2 2024 was $18 million, with a net income margin of 20%.
- Adjusted EBITDA for Q2 2024 was $20 million, representing 23% of net sales.
- The company launched HELIOGEN™, their first xenograft product.
Headline financials
Revenue & EPS history
Mimedx · Revenue · Quarterly
$87.2M
Forward guidance
MiMedx expects net sales growth to be in the mid-to-high single-digits as a percentage compared to 2023, due principally to the ongoing uncertainty surrounding Medicare reimbursement policy for skin substitutes in the private office and adjacent care settings. Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an adjusted EBITDA margin above 20%.
Tailwinds
- Continued expansion of footprint in various surgical settings.
- Commitment to high-quality clinical and scientific research.
- Full market release of first xenograft product, HELIOGEN.
- Expects annual net sales growth in the low double-digits as a percentage.
- Expects adjusted EBITDA margin above 20%.
Headwinds
- Uncertainty surrounding Medicare reimbursement policy for skin substitutes in the private office and adjacent care settings.
- Commercial challenges as a result of certain competitive behavior.
- Several companies continue to engage in schemes to sell artificially high-priced, yet clinically unproven, skin substitutes primarily in the private office, by sharing a substantial portion of the revenue with treating physicians.
- Higher than normal employee and customer attrition during the quarter as people were swept up by the promise of riches.
- Ongoing uncertainty related to Medicare’s reimbursement of these products, based upon recently proposed Local Coverage Determinations, and headwinds relating to turnover of certain of our sales team and customers.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+1.7%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+7.2%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+37.9%
Q1 2023
Best reaction
-23.3%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.1% | +6.2% | +8.2% | |
| Q4 2025 | -0.9% | -8.8% | -28.8% | |
| Q3 2025 | +2.6% | +7.0% | -4.3% | |
| Q1 2025 | -8.1% | -3.9% | -6.5% | |
| Q4 2024 | +1.6% | +1.1% | -5.9% | |
| Q3 2024 | +17.9% | +22.7% | +59.2% | |
| Q2 2024 | -12.0% | -17.7% | -9.9% | |
| Q1 2024 | +16.8% | +17.7% | +13.7% | |
| Q4 2023 | -2.9% | -1.7% | -8.3% | |
| Q3 2023 | +6.7% | +10.9% | +26.5% | |
| Q2 2023 | -4.6% | -4.2% | -8.1% | |
| Q1 2023 | +37.9% | +49.1% | +50.4% | |
| Q4 2022 | -11.4% | -6.4% | -29.0% | |
| Q3 2022 | -3.6% | +1.3% | +12.6% | |
| Q2 2022 | +8.2% | +15.5% | +2.3% | |
| Q1 2022 | +11.1% | -8.9% | -4.8% | |
| Q4 2021 | +1.4% | -1.6% | -4.0% | |
| Q3 2021 | +18.8% | +22.6% | +2.5% | |
| Q2 2021 | -2.5% | +1.4% | +23.4% | |
| Q1 2021 | -2.9% | -5.0% | +2.0% | |
| Q4 2020 | -15.3% | -13.4% | +13.8% | |
| Q3 2020 | +3.4% | -8.2% | -5.6% | |
| Q2 2020 | +2.3% | +4.2% | +14.4% | |
| Q2 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2020 | +8.2% | +3.2% | +18.2% | |
| Q4 2018 | +8.2% | +3.2% | +18.2% | |
| Q4 2019 | +8.2% | +3.2% | +18.2% | |
| Q2 2019 | +8.2% | +3.2% | +18.2% | |
| Q1 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2019 | +8.2% | +3.2% | +18.2% | |
| Q3 2019 | +8.2% | +3.2% | +18.2% | |
| Q4 2017 | -21.6% | -22.1% | -14.0% | |
| Q3 2018 | -1.3% | -8.6% | -7.0% | |
| Q3 2017 | +4.1% | +8.7% | -4.9% | |
| Q2 2017 | +0.7% | +2.1% | +5.9% | |
| Q1 2017 | +8.2% | +19.1% | +17.5% | |
| Q4 2016 | -3.9% | +3.4% | +9.8% | |
| Q3 2016 | +4.9% | +8.0% | +19.1% | |
| Q2 2016 | -0.9% | -1.7% | -5.6% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -23.3% | — | — | |
| Q2 2015 | -13.5% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +8.7% | — | — | |
| Q3 2014 | +13.2% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | -3.8% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | -2.2% | — | — | |
| Q4 2012 | +8.5% | — | — | |
| Q3 2012 | +13.5% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -4.2% | — | — | |
| Q2 2011 | -2.5% | — | — | |
| Q1 2011 | -3.7% | — | — | |
| Q4 2010 | +5.8% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | -4.8% | — | — | |
| Q1 2010 | +4.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro